Ionis Pharmaceuticals Inc (IONS) Shares Outstanding 2006–TTM

Name: Ionis Pharmaceuticals Inc (IONS) shares outstanding history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Ionis Pharmaceuticals Inc annual shares outstanding for fiscal 2025 was 160 million shares, an increase of 6.7% from 150 million shares in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

IONS Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Shares Outstanding (M)	—	160M	150M	143M	142M	141M	140M	143M	134M	126M	121M	120M	118M	111M	101M	100M	99M	98M	95M	84M	74M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IONS Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	—	165M	162M	161M	182M	159M	158M	149M	146M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Shares Outstanding at Comparable Companies

APGE Shares Outstanding — Apogee Therapeutics, Inc. Common Stock
PTGX Shares Outstanding — Protagonist Therapeutics Inc
KRYS Shares Outstanding — Krystal Biotech Inc
KYMR Shares Outstanding — Kymera Therapeutics Inc
SYRE Shares Outstanding — Spyre Therapeutics Inc.
CRNX Shares Outstanding — Crinetics Pharmaceuticals Inc

More IONS metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All IONS financial statements → Interactive IONS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.